Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Consistent antihypertensive efficacy of the RNA interference therapeutic zilebesiran: Subgroup results from the KARDIA-1 phase 2 study in patients with hypertension

Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan

KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

Unmet Need in a Contemporary Cohort of Tafamidis-Treated Transthyretin Amyloid Cardiomyopathy Patients

Durable Reductions in Circulating Angiotensinogen and Blood Pressure 6 Months after Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients

Insights from the HELIOS-A Study

This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.

Safety and Tolerability of Zilebesiran, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Obese Patients with Hypertension

Subgroup Results from KARDIA-2: Impact of Demographic and Baseline Disease Characteristics on Zilebesiran Response in Patients with Hypertension Uncontrolled by a Standard Oral Antihypertensive

ATTRv-PN Expert Opinion Slide Deck

Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

Potential Predictors of PH1 in Pediatric Patients

The handout details potential clinical characteristics that pediatric patients may present with which should warrant suspicion for PH1.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.